On March 22, 2023, Flare Therapeutics, Inc. closed the transaction. The company has issued 102,218,898 series B preferred shares for gross proceeds of $122,999,999.9634 in the transaction. The round of funding co-led by GordonMD Global Investments LP and Pfizer Venture Investments LLC.

The transaction also included participation from new investors, Agent Capital, LLC, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis AG, Shangbay Capital, LLC, Pavilion Capital Partners LLC, returning investors, Third Rock Ventures, LLC, Boxer Capital LLC, Nextech Invest Ltd., Casdin Capital, LLC, Invus Financial Advisors, LLC and Eventide Asset Management, LLC. The transaction has been oversubscribed. As a part of transaction, Craig D. Gordon and Irena Melnikova has joined the board of directors of the company.